Coupling factor 6-induced prostacyclin inhibition is enhanced in vascular smooth muscle cells from spontaneously

Tomohiro Osanai1, Hirofumi Tomita, Masahiro Yamada

  • 1Department of Cardiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. osanait@cc.hirosaki-u.ac.jp

Insights

Coupling factor 6 (CF6) suppresses prostacyclin generation in vascular smooth muscle cells. This effect is amplified in spontaneously hypertensive rats due to increased CF6 production and sensitivity, impacting vascular tone.

Area of Science:

  • Cardiovascular Physiology
  • Vascular Biology
  • Molecular Medicine

Background:

  • Coupling factor 6 (CF6) is known to reduce endothelial prostacyclin production.
  • The specific role of CF6 in resistance arterioles, crucial for vascular tone, remains unclear.
  • Vascular smooth muscle cells (VSMCs) are key regulators of vascular tone.

Purpose of the Study:

  • To investigate the impact of endogenous and exogenous CF6 on prostacyclin generation in cultured VSMCs.
  • To determine the role of CF6 in resistance arterioles of spontaneously hypertensive rats (SHRs) compared to Wistar-Kyoto (WKY) rats.

Main Methods:

  • Cultured mesenteric resistance arteriole VSMCs from SHRs and WKY rats.
  • Measured CF6 gene expression, mRNA degradation rates, and protein release.
  • Assessed prostacyclin generation and arachidonic acid release.
  • Utilized CF6 antibodies, tyrosine kinase inhibitors (PP1), and receptor blockers (ADP, efrapeptin, anti-ATP synthase antibody).

Main Results:

  • SHR-derived VSMCs exhibited significantly higher CF6 gene expression and release compared to WKY rats.
  • Prostacyclin generation was lower in SHR VSMCs but restored by CF6 neutralization.
  • Exogenous CF6 dose-dependently suppressed arachidonic acid release, with a greater effect in SHRs.
  • CF6-induced suppression of prostacyclin was blocked by PP1, ADP, efrapeptin, and anti-ATP synthase antibody.

Conclusions:

  • CF6 suppresses prostacyclin generation in resistance arteriole VSMCs via autocrine/paracrine mechanisms.
  • Enhanced CF6 overproduction and hyperresponsiveness contribute to its elevated role in SHRs.
  • These findings highlight CF6's significance in regulating vascular tone and its potential role in hypertension.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Spin–Spin Coupling: Three-Bond Coupling (Vicinal Coupling)01:22

Spin–Spin Coupling: Three-Bond Coupling (Vicinal Coupling)

Vicinal or three-bond coupling is commonly observed between protons attached to adjacent carbons. Here, nuclear spin information is primarily transferred via electron spin interactions between adjacent C‑H bond orbitals. This generally favors the antiparallel arrangement of spins, so 3J values are usually positive.
The extent of coupling depends on the C‑C bond length, the two H‑C‑C angles, any electron-withdrawing substituents, and the dihedral angle between the involved orbitals. The...